Keywords: medimmune, 3rd-qtr, loss, grows, four-fold, drugmaker, saw
MedImmune's 3rd-qtr loss grows four-fold
Article | 01 November 2004
US drugmaker MedImmune saw its third quarter losses quadruple to $65 million, or $0.26 per share, from the year-earlier period's $16 million, or $0.16, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Sanofi and Regeneron's dupilumab shows 87% reduction in risk of asthma exacerbations
